IDRO, Collegiate Jihad ink agreement to produce anti-cancer drugs

IDRO, Collegiate Jihad unveil three joint products

The Industrial Development and Renovation Organization and the Collegiate Jihad unveiled three joint products in the field of high-tech industries. IDRO chairman Eng. Shafei attended the unveiling ceremony, which was held at an exhibition of the Collegiate Jihad’s achievements in the Goftegoo Park.

Eng. Gholamreza Shafei, the chairman of the board of directors of the Industrial Development and Renovation Organization addressed the ceremony, saying that the unveiled products, namely the her2 anti-cancer drug, the UPS system, and the phosphate fertilizers, have been products using IDRO’s financial resources or other resources which are allocated to support modern industries. The products are now ready to be manufactured in commercial scale, he added.

Referring to the specifications of the her2 anti-cancer drug, he said that the drug is passing experimental phases and is has been successfully tested on mice. In the near future, it will be tested on human and will be produced in large scale, he said.

The IDRO chairman added: “The her2 drug will be used in the treatment of breast cancer, which is one of the most rampant cancers in the country.”

Regarding the importance of producing phosphate fertilizers, Eng. Shafei said: “Phosphate fertilizers, which have been produced by IDRO in the form of a modern industry plan in cooperation with Collegiate Jihad, will be used as a substitute for urea fertilizers and will reduce the volume of necessary urea fertilizers by one fourth. In addition to being economically justified, phosphate fertilizers are anti-algae. They will not pollute the environment due to being fully absorbed by plants.”

The deputy minister of industry, mine, and trade expressed IDRO’s preparedness to invest in commercializing the production of the unveiled products. He added that an agreement will be held with Collegiate Jihad and Ebn-e Sina Research Center with the aim of producing five anti-cancer drugs in large scale. Signing the agreements will boost cooperation between IDRO and universities in the field of modern industries, he noted.

The agreement for producing the anti-cancer drugs was then signed by Eng. Shafei, the chairman of the board of directors of IDRO, and Mohammad Mehdi Akhoondi, the director of Ebn-e Sina modern biological technologies research center of Collegiate Jihad.

It should be mentioned that according to the agreement, a center will be established under a joint investment by IDRO and Collegiate Jihad, for producing 5 monoclonal antibodies, especial for curing cancers. In the second phase, five other treatment antibodies will be produced. Meanwhile, the center has the capacity to meet domestic needs for diagnostic and research antibodies.

About 593 billion rials will be needed to be invested in the plan. The produced drugs will be used in the treatment of lung, breast, kidney, skin, and colon cancers, as well as multiple sclerosis or MS disease.